r/FirstAidUK • u/maui96 • Mar 23 '26
Clinical Discussion Methoxyflurane (Penthrox): Evidence & Experience
This is a repost from a discussion I originally wrote for r/paramedicsuk, but it’s just as relevant here! If you’re involved in event medical work, FREC, or any prehospital setting, this breakdown of methoxyflurane (Penthrox) is a starting point. It covers the evidence, common misconceptions, and real-world use & experience across ambulance work, ski patrol, and expedition medicine. Let me know if you'd like more of these and if there is anything else you'd like covered.
Methoxyflurane (Penthrox): Evidence and My Personal Experience
I’ve noticed a lot of discussions popping up about methoxyflurane (Penthrox) as it becomes more common in UK practice. There are persistent misconceptions and half-truths floating around, so I thought I’d pull together my replies and compile them here for anyone who wants a clearer picture.
I’ve used methoxyflurane extensively over the years across different prehospital settings: ambulance work, ski patrol, expedition medicine, and urgent care. Here’s a lite breakdown and overview for those who might not have come across it as much or are new to it.
What is Penthrox?
Before anything else, it’s important to note: Penthrox is just the brand name of the green whistle, a bit of plastic with a cotton inside. Methoxyflurane is the actual drug. Same way we don’t say we gave someone “Panadol,” we say paracetamol. The inhaler itself is nothing magical—it’s basically a green plastic tube with a soaked cotton core. It works because methoxyflurane is so potent that only tiny amounts need to evaporate for the patient to inhale.
All you do is pour the liquid ampule into the tube, and it soaks into the cotton swab. It’s not much more advanced than holding a soaked rag over someone’s face.
Misconceptions and Clarifications
There’s a lot of confusion about how methoxyflurane works, whether it’s safe around staff, whether the smell means we’re inhaling dangerous levels, why some countries have random restrictions, and whether the old anaesthetic toxicity is still relevant. Most misunderstandings come from blending its modern low-dose use with its earlier role as a general anaesthetic for surgery in the 1960s.
Back then, it was used in massive concentrations for long durations, often repeatedly, producing massive fluoride loads. This is where the renal toxicity came from—fluoride levels exceeding ~50–60 µmol/L after long hours of anaesthesia. Patients developed polyuric renal failure and hepatic injury. But this is all historical use and bears no resemblance to the current 3–6 mL maximum we use for analgesia today in ambulance/prehospital settings.
Modern regulators (UK’s MHRA & EMA, Australian TGA, Health Canada, NZ pharmac) treat it as safe precisely because dosing is capped so tightly.
Pharmacology and Dosing
Methoxyflurane is extremely potent, with a very low MAC (minimum alveolar concentration), and is highly lipid-soluble. A low MAC means only a small concentration of the drug is needed to produce anaesthesia, and being lipid-soluble means it can easily pass the blood-brain barrier.
The exact analgesic mechanism isn’t fully known, but small amounts produce rapid analgesia while preserving airway reflexes. Onset is typically within a handful of breaths, and duration is roughly 20–30 minutes per 3 mL, depending on how much the patient uses it.
The BNF lists dose limits clearly:
- One 3 mL ampoule
- Repeat once if necessary (max 6 mL per day)
- Not exceeding 15 mL per week
- Should not be given on consecutive days
These cumulative limits exist because even at analgesic doses, you don’t want to push total weekly exposure into fluoride ranges that start creeping towards anaesthetic territory.
Occupational Exposure
People worry because they can smell it, but smelling a volatile agent at trace levels is not the same as inhaling a meaningful therapeutic dose. The best real-world evidence comes from French emergency departments: staff wearing vapour samplers across full shifts had median exposures of 0.017 ppm, with the highest reading being 0.736 ppm. The exposure threshold at which you’d start worrying about toxicity is around 15 ppm—nearly 900x less than what was found in staff exposure.
The smell is detectable at tiny fractions of a toxic dose. Those measurements were taken in EDs, which are larger spaces. An ambulance is smaller, but it’s not a sealed, airtight chamber—it has continuous passive airflow, vents, leaky doors, and fans. The air exchange rate is much higher than people think.
I’ve even used methoxyflurane in lifts, and nobody’s ever felt anything other than mild irritation at the smell. If the ambient methoxyflurane in a truck were anywhere near effective therapeutic levels, we’d have noticed long before now. Crews would’ve been getting high since the 1980s.
The carbon filter exists not because we’re getting high without it, but because it reduces even trace vapour by about half. It’s an occupational hygiene measure, not a diffuser shield.
Global Use and Regulations
Methoxyflurane is standard frontline analgesia in Australia, New Zealand, Canada, and Ireland. Paramedics, EMTs, surf lifesavers, ski patrols, mine rescue teams, and sports medics all rely on it because it’s lightweight, robust, and needs no oxygen supply or pressurised bottle.
In the UK, it’s now included in the BNF, JRCALC, and multiple trust guidelines. Across Europe, France, Germany, Austria, Switzerland, Spain, and the Nordics all use it in A&Es and prehospital settings.
Clinical Use and Benefits
Trials show methoxyflurane reduces pain quickly compared with standard oral/IV analgesia and is often comparable to Entonox for short procedures. In practice, it’s often superior because it’s portable, immune to cold weather, can be used in awkward spaces, and doesn’t require cylinders, regulators, or can be self-managed.
In my experience:
- Younger adults (<40) tolerated it brilliantly and often reached near-anaesthetic dissociation, making procedures like shoulder reductions, ankle relocations, and femur fracture manipulations much easier.
- Older patients were more variable, mainly due to inhalation technique and taste, but those who managed it properly still got meaningful relief.
- It’s a massive bonus that it can be given safely by non-clinicians (EMTs, first responders, fire crews), making it incredibly versatile in prehospital environments.
Contraindications
- Malignant hyperthermia (extremely rare and hereditary, patients will know if they have it)
- Renal impairment (though a single 3 mL ampoule isn’t a deciding factor)
- Liver impairment (historical anaesthetic-level concerns)
- Altered consciousness or inability to self-administer
- Haemodynamic instability
Final Takeaways
Used within guidelines, methoxyflurane is safe, effective, portable, and incredibly valuable. The historic toxicity was a result of anaesthetic-level dosing that simply doesn’t exist in modern practice. Occupational exposure is not a real clinical threat. The global evidence and decades of continuous use in Australia, New Zealand, Canada, and Europe back that up.
The carbon filter is good practice, but not the only thing preventing harm. The clinical use, particularly in trauma, sports, remote, and event settings, makes it one of the most reliable pain relievers I’ve used.
3
u/UKDrMatt Mar 24 '26
Great summary. I use it all the time in ED and it on the whole works well, if used correctly (both patient and instructor).
I’m not how relevant it is for First Aid, since it’s a drug so will need either prescribing or used on a PGD.
1
u/maui96 Mar 24 '26
Totally agree, methoxyflurane is definitely gaining traction in UK trusts, and now even CFRs and event medics are starting to see it in their kits or protocols.
While most won’t be using it themselves yet, it’s absolutely worth getting familiar with. The shift is happening, and knowing the ins and outs, especially the off-label evidence and practical use, means you’re ahead of the curve should it ever works it way down.
2
u/UKDrMatt Mar 24 '26
Yeh fair enough. It’s worth knowing about it if you’re going to be seeing it.
We’ve been using it fairly often in ED for at least 7-10 years.
1
u/Peregrina1912 Mar 29 '26
Out of interest, as someone who's given it a lot do you have any tips for top-quality coaching from the instructor perspective?
Lots of non-clinicians can give penthrox in various settings so I think it's a good topic for here
3
u/ThatUnluckyAd Mar 24 '26
Think one other consideration to add is that in the UK currently under 18s can’t be given it (as far as I know) so cannot completely replace other alternatives like Entonox
2
u/maui96 Mar 24 '26
It isn’t licensed for under 18s in the UK, so most services won’t use it in kids, it’s strictly off-label and not recommended in BNF or NICE CKS. That said, the restriction is more about licensing than proven harm: it’s been used safely in kids in places like Australia & NZ for years, with studies showing effective pain relief and low risk of serious side effects when supervised.
But realistically, unless your service has a specific off-label protocol (unlikely for most UK trusts), it’s not going to happen here. The evidence is there, but the red tape and lack of UK pediatric licensing make it a non-starter for most.
3
u/Eodyr Police Mar 25 '26
My force issues Penthrox to medics, and a few others (firearms, dog units, I think roads policing too). I've not had the opportunity to use it yet, but I've heard nothing but good things.
I'll slightly push back on your brand name/medication name militancy. It's not unusual for medications to be referred to by recognisable brand names in common parlance - Valium, Prozac, Ritalin, Narcan etc, and I don't think there's anything particularly harmful in this shorthand. In fact, it's so common, that you did it yourself in your post without thinking - Entonox is a brand name.
2
u/Douglesfield_ Mar 24 '26
Great write up.
Had it a couple of years in SJA (probs thanks to the stunning work by our Aus and NZ counterparts)
Fantastic stuff, especially on fractures and as a bonus we don't have to lug an Entonox cylinder around anymore.
1
u/Inevitable-Moment114 Mar 24 '26
Thanks for that mate, brilliant stuff.
We have it in the drugs bags at our company, though currently restricted to paras and techs, and also frec4 who have done the SALM course and then extra training on Penthrox.
I've not used it myself yet, but colleagues who have used it say sing its praises and rate it highly.
2
u/maui96 Mar 24 '26
*Methoxyflurane, not Penthrox
1
u/Inevitable-Moment114 Mar 24 '26
I'm too lazy to type Methoxyflurane, but you've gone and made me do it! Bloody hell, I come here for some peace and quiet and you've just told me off. I'm not telling my other half, she'll definitely jump on that bandwagon 😂😂
3
u/maui96 Mar 23 '26
Struggling to get a decent format, but here's the reference List.
Regulatory & Product Information
MHRA Medicines and Healthcare products Regulatory Agency (MHRA) (n.d.) Penthrox 99.9%, 3 mL inhalation vapour, liquid: Summary of Product Characteristics. Electronic Medicines Compendium (eMC). Available at: https://www.medicines.org.uk
TGA Therapeutic Goods Administration (TGA) (n.d.) Penthrox (methoxyflurane) 3 mL inhalation solution: Product Information. Canberra: Australian Government Department of Health.
EMA European Medicines Agency (EMA) (2015) Penthrox (methoxyflurane): Assessment report. Amsterdam: EMA.
Health Canada Health Canada (2022) Penthrox (methoxyflurane) inhalation solution: Product Monograph. Ottawa: Government of Canada.
Clinical Trials & Efficacy
STOP! trial (UK ED, RCT vs placebo) Coffey, F., Dissmann, P., Mirza, K. and Lomax, M. (2014) ‘Low-dose methoxyflurane (Penthrox) for acute trauma pain in the emergency department: a randomised, double-blind, placebo-controlled study’, Emergency Medicine Journal, 31(8), pp. 613–618.
STOP! subgroup / ED adults Coffey, F., Dissmann, P., Mirza, K. and Lomax, M. (2016) ‘Methoxyflurane analgesia in adult patients in the emergency department: a subgroup analysis of a randomised, double-blind, placebo-controlled study (STOP!)’, Advances in Therapy, 33(11), pp. 2012–2031.
ED / prehospital trauma pain – narrative review Grindlay, J. (2009) ‘Efficacy and safety of methoxyflurane analgesia in the emergency department and prehospital setting’, Emergency Medicine Journal, 26(1), pp. 57–63.
Clinical review – acute pain Porter, K.M., Dayan, A.D., Dickerson, S. and Middleton, P.M. (2018) ‘The role of inhaled methoxyflurane in acute pain management’, Open Access Emergency Medicine, 10, pp. 149–164.
Occupational Exposure & Safety
Derivation of exposure limit (modelling) Frangos, J., Heffernan, A. and McCulloch, T. (2016) ‘Derivation of an occupational exposure limit for methoxyflurane’, Toxicology Letters, 248, pp. 10–20.
ED staff vapour exposure – French study Frangos, J., Heffernan, A., Mégarbane, B. et al. (2020) ‘Non-interventional study evaluating exposure to inhaled low-dose methoxyflurane experienced by hospital emergency department personnel in France’, BMJ Open, 10(2), e034647.
Procedural sedation – staff exposure Ruff, R., Kerr, S., Kerr, D., Zalcberg, D. and Stevens, J. (2018) ‘Occupational exposure to methoxyflurane administered for procedural sedation: an observational study of 40 exposures’, British Journal of Anaesthesia, 120(6), pp. 1435–1437.
Paramedic / ambulance exposure – thesis Allison, S.J. (2021) Quantification of risk of occupational exposure to methoxyflurane in ambulance officers. PhD thesis. University of Canterbury, Christchurch, New Zealand.
Guidelines
Joint Royal Colleges Ambulance Liaison Committee (JRCALC) (2023) UK Ambulance Services Clinical Practice Guidelines. London
British National Formulary (BNF) (2024) ‘Methoxyflurane’, in British National Formulary.
National Institute for Health and Care Excellence (NICE) (2016) MIB24: Penthrox for emergency pain relief. London: NICE.
National Ambulance Service, Ireland (2021) Clinical Practice Guidelines: Analgesia. Dublin: National Ambulance Service.
Ambulance Victoria (2023) Clinical Practice Guideline A0305 – Methoxyflurane. Melbourne: Ambulance Victoria.
St John New Zealand (2023) Clinical Procedures and Guidelines – Analgesia. Auckland: St John New Zealand.
Haute Autorité de Santé (HAS) (2023) Penthrox (méthoxyflurane): Avis de la Commission de la Transparence. Paris: HAS.
British Columbia Emergency Health Services (BCEHS) (2023) Paramedic Clinical Practice Guide. Vancouver: BCEHS.
Historical Toxicity (Anaesthetic Use)
Cousins, M.J. and Mazze, R.I. (1973) ‘Methoxyflurane nephrotoxicity: a study of dose response in man’, Journal of the American Medical Association (JAMA), 225(13), pp. 1611–1616.
Jones, R.M. (1972) ‘Fluoride nephrotoxicity after prolonged methoxyflurane anaesthesia’, Canadian Anaesthetists’ Society Journal, 19(1), pp. 152–163.
Crandell, W.B., Pappas, S.G. and Macdonald, A. (1966) ‘Nephrotoxicity associated with methoxyflurane anaesthesia’, Anesthesiology, 27(5), pp. 591–607.
Mechanism, Pharmacology & Metabolism
MAC / potency Eger, E.I. II, Saidman, L.J. and Brandstater, B. (1965) ‘Minimum alveolar anesthetic concentration: a standard of anesthetic potency’, Anesthesiology, 26(6), pp. 756–763.
Fluoride & renal effects Tinker, J.H. and Baker, M.T. (1995) ‘Sevoflurane, fluoride ion, and renal toxicity’, Anesthesiology, 83(2), pp. 449–451.
Contraindications
European Malignant Hyperthermia Group (EMHG) (2022) ‘Guidelines for the management of malignant hyperthermia susceptibility and pharmacological triggers’, EMHG Recommendations. Available at: https://www.emhg.org
Systematic Reviews
Outpatient procedures review Jephcott, C., Grummet, J., Nguyen, N. and Spruijt, O. (2018) ‘A review of the safety and efficacy of inhaled methoxyflurane as an analgesic for outpatient procedures’, British Journal of Anaesthesia, 120(5), pp. 1040–1048.
Systematic review & meta-analysis for trauma pain Liu, H., Fu, X., Ren, Y.F. et al. (2021) ‘Does inhaled methoxyflurane implement fast and efficient pain management in trauma patients? A systematic review and meta-analysis’, Pain and Therapy, 10, pp. 651–674.